Shares of Baxter International (BAX) tumbled 6.60% in pre-market trading on Thursday following the release of its second-quarter 2025 earnings report, which fell short of analyst expectations and was accompanied by cautious guidance.
The healthcare company reported adjusted earnings per share of $0.54, missing the consensus estimate of $0.61. Revenue for the quarter came in at $2.81 billion, slightly below the expected $2.823 billion. Baxter's adjusted operating income of $423 million also fell short of the $452.3 million analysts had projected, indicating pressure on the company's profitability.
Adding to investor concerns, Baxter provided a conservative outlook for the third quarter and full year 2025. The company expects Q3 sales growth from continuing operations of 6% to 7% on a reported basis, with adjusted earnings from continuing operations, before special items, of $0.58 to $0.62 per diluted share. For the full year, Baxter forecasts revenue growth of 6-7% and adjusted EPS in the range of $2.42 to $2.52. This guidance suggests ongoing challenges in the healthcare sector and potential headwinds for Baxter's business performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.